Catalent Inc (CTLT) Receives $49.71 Average Target Price from Analysts

Shares of Catalent Inc (NYSE:CTLT) have earned an average recommendation of “Buy” from the fourteen research firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $49.71.

CTLT has been the topic of a number of analyst reports. ValuEngine lowered shares of Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, June 5th. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, July 3rd. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Catalent from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Wednesday, August 29th.

In other Catalent news, Director Donald E. Morel, Jr. bought 10,000 shares of Catalent stock in a transaction on Thursday, September 13th. The stock was bought at an average price of $43.00 per share, with a total value of $430,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.70% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in CTLT. Millennium Management LLC raised its stake in shares of Catalent by 4,244.2% during the 2nd quarter. Millennium Management LLC now owns 1,200,267 shares of the company’s stock worth $50,279,000 after buying an additional 1,172,638 shares during the last quarter. Redmile Group LLC acquired a new position in shares of Catalent during the 2nd quarter worth $27,725,000. Champlain Investment Partners LLC raised its stake in shares of Catalent by 19.2% during the 1st quarter. Champlain Investment Partners LLC now owns 3,627,390 shares of the company’s stock worth $148,941,000 after buying an additional 583,675 shares during the last quarter. Macquarie Group Ltd. raised its stake in shares of Catalent by 25.2% during the 2nd quarter. Macquarie Group Ltd. now owns 2,349,059 shares of the company’s stock worth $98,402,000 after buying an additional 472,228 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Catalent by 59.8% during the 1st quarter. Wells Fargo & Company MN now owns 1,146,493 shares of the company’s stock worth $47,074,000 after buying an additional 429,061 shares during the last quarter. 91.96% of the stock is owned by institutional investors and hedge funds.

NYSE:CTLT opened at $43.03 on Friday. Catalent has a 1-year low of $36.73 and a 1-year high of $47.87. The company has a debt-to-equity ratio of 2.44, a quick ratio of 1.79 and a current ratio of 2.15. The firm has a market capitalization of $6.18 billion, a P/E ratio of 27.06, a PEG ratio of 2.54 and a beta of 1.42.

Catalent (NYSE:CTLT) last posted its quarterly earnings data on Tuesday, August 28th. The company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.06. Catalent had a net margin of 3.39% and a return on equity of 20.42%. The firm had revenue of $685.30 million for the quarter, compared to analyst estimates of $690.69 million. During the same period last year, the firm posted $0.65 EPS. Catalent’s quarterly revenue was up 11.1% on a year-over-year basis. analysts forecast that Catalent will post 1.72 earnings per share for the current fiscal year.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Recommended Story: Should You Consider an Index Fund?

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply